Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 18-34

  Izzi, Valerio ^a   Masuelli, Laura ^b   Tresoldi, Ilaria ^a   Foti, Calogero ^a   Modesti, Andrea ^a   Bei, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Immune response; Innate immunity; MAb based therapy; Malignant mesothelioma; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BETA INTERFERON; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; MESOTHELIN; METHOTREXATE; MONENSIN; MYCOBACTERIUM VACCAE VACCINE; MYCOBACTERIUM VACCINE; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; WNT1 PROTEIN; WNT2 PROTEIN;

CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL DAMAGE; CELL DEATH; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; HUMAN; IMMUNITY; IMMUNOMODULATION; IMMUNOPOTENTIATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLEURAL EFFUSION; MESOTHELIUM CELL; MONOCYTE; NONHUMAN; ONCOGENE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SHORT SURVEY; SKIN TOXICITY; SYSTEMIC DISEASE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 84861453989     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.034     Document Type: Review

References (193)

1. Antman K.H. Natural history and epidemiology of malignant mesothelioma. Chest 1993, 103:373-376.
2. Fletcher J.A., Otis C.N. Pleura and peritoneum. The Cancer Handbook 2008, 767-776. John Wiley & Sons. M.R. Alison (Ed.).
3. Attanoos R.L., Gibbs A.R. Pathology of malignant mesothelioma. Histopathology 1997, 30:403-418.
4. Walker C., Everitt J., Barrett J.C. Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am. J. Indust. Med. 1992, 21:253-273.
5. Carbone M., Bedrossian C.W. The pathogenesis of mesothelioma. Sem. Diagn. Pathol. 2006, 23:56-60.
6. Kim R., Emi M., Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006, 119:254-264.
7. Branchaud R.M., Garant L.J., Kane A.B. Pathogenesis of mesothelial reactions to asbestos fibers. Monocyte recruitment and macrophage activation. Pathobiology 1993, 61:154-163.
8. Bei R., Masuelli L., Palumbo C., Tresoldi I., Scardino A., Modesti A. Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules. Int. Rev. Immunol. 2008, 27:137-175.
9. Chahinian A.P., Pajak T.F., Holland J.F., Norton L., Ambinder R.M., Mandel E.M. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann. Intern. Med. 1982, 96:746-755.
10. Selikoff I.J., Hammond E.C., Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980, 46:2736-2740.
11. Carbone M., Pass H.I., Rizzo P., Marinetti M., Di Muzio M., Mew D.J., Levine A.S., Procopio A. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994, 9:1781-1790.
12. Bielefeldt-Ohmann H., Jarnicki A.G., Fitzpatrick D.R. Molecular pathobiology and immunology of malignant mesothelioma. J. Pathol. 1996, 178:369-378.
13. Garlepp M.J., Leong C.C. Biological and immunological aspects of malignant mesothelioma. Eur. Respir. J. 1995, 8:643-650.
14. Jantz M.A., Antony V.B. Pathophysiology of the Pleura. Respiration 2008, 75:121-133.
15. van Grevenstein W.M., Aalbers A.G., Ten Raa S., Sluiter W., Hofland L.J., Jeekel H., van Eijck C.H. Surgery-derived reactive oxygen species produced by polymorphonuclear leukocytes promote tumor recurrence. Studies in an in vitro model. J. Surg. Res. 2007, 140:115-120.
16. Manning P., Cookson M.R., McNeil C.J., Figlewicz D., Shaw P.J. Superoxide-induced nitric oxide release from cultured glial cells. Brain Res. 2001, 911:203-210.
17. Kinnula V.L., Raivio K.O., Linnainmaa K., Ekman A., Klockars M. Neutrophil and asbestos fiber-induced cytotoxicity in cultured human mesothelial and bronchial epithelial cells. Free Radic. Biol. Med. 1995, 18:391-399.
18. Phillips B.J., Anderson D., Gangolli S.D. Influence of phagocyte-derived active oxygen species in tissue responses to tumor promoters and irritants. Food Chem. Toxicol. 1986, 24:681-683.
19. Choe N., Tanaka S., Xia W., Hemenway D.R., Roggli V.L., Kagan E. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ. Health Perspect. 1997, 105:1257-1260.
20. Tanaka S., Choe N., Hemenway D.R., Zhu S., Matalon S., Kagan E. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. J. Clin. Invest. 1998, 102:445-454.
21. Miles A.M., Owens M.W., Milligan S., Johnson G.G., Fields J.Z., Ing T.S., Kottapalli V., Keshavarzian A., Grisham M.B. Nitric oxide synthase in circulating vs. extravasated polymorphonuclear leukocytes. J. Leukoc. Biol. 1995, 58:616-622.
22. Marrogi A., Pass H.I., Khan M., Metheny-Barlow L.J., Harris C.C., Gerwin B.I. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 2000, 60:3696-3700.
23. Arriero M.M., Rodríguez-Feo J.A., Celdrán A., Sánchez de Miguel L., González-Fernández F., Fortes J., Reyero A., Frieyro O., de la Pinta J.C., Franco A., Pastor C., Casado S., López-Farré A. Expression of endothelial nitric oxide synthase in human peritoneal tissue: regulation by Escherichia coli lipopolysaccharide. J. Am. Soc. Nephrol. 2000, 11:1848-1856.
24. Chen J.Y., Chiu J.H., Chen H.L., Chen T.W., Yang W.C., Yang A.H. Human peritoneal mesothelial cells produce nitric oxide: induction by cytokines. Perit. Dial. Int. 2000, 20:772-777.
25. Kamp D.W., Shacter E., Weitzman S.A. Chronic inflammation and cancer: the role of the mitochondria. Oncology 2011, 25:410-413.
26. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
27. Srivastava R.K., Lohani M., Pant A.B., Rahman Q. Cyto-genotoxicity of amphibole asbestos fibers in cultured human lung epithelial cell line: role of surface iron. Toxicol. Indust. Health 2010, 26:575-582.
28. Nishiike T., Nishimura Y., Wada Y., Iguchi H. Production of nitric oxide elevates nitrosothiol formation resulting in decreased glutathione in macrophages exposed to asbestos or asbestos substitutes. Arch. Toxicol. 2005, 79:83-89.
29. Haslam P.L., Lukoszek A., Merchant J.A., Turner-Warwick M. Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma. Clin. Exp. Immunol. 1978, 31:178-188.
30. Kagan E., Jacobson R.J., Yeung K.Y., Haidak D.J., Nachnani G.H. Asbestos-associated neoplasms of B cell lineage. Am. J. Med. 1979, 67:325-330.
31. Moalli P.A., MacDonald J.L., Goodglick L.A., Kane A.B. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am. J. Pathol. 1987, 128:426-445.
32. Kinnula V.L., Aalto K., Raivio K.O., Walles S., Linnainmaa K. Cytotoxicity of oxidants and asbestos fibers in cultured human mesothelial cells. Free Radic. Biol. Med. 1994, 16:169-176.
33. Marczynski B., Rozynek P., Kraus T., Schlosser S., Raithel H.J., Baur X. Levels of 8-hydroxy-2X-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat. Res. 2000, 468:195-202.
34. Cardile V., Renis M., Scifo C., Lombardo L., Gulino R., Mancari B., Panico A. Behaviour of the new asbestos amphibole fluoro-edenite in different lung cell systems. Int. J. Biochem. Cell Biol. 2004, 36:849-860.
35. Yang H., Rivera Z., Jube S., Nasu M., Bertino P., Goparaju C., Franzoso G., Lotze M.T., Krausz T., Pass H.I., Bianchi M.E., Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl. Acad. Sci. USA 2010, 107:12611-12616.
36. Antony V.B. Immunological mechanisms in pleural disease. Eur. Respir. J. 2003, 21:539-544.
37. Kato S., Yuzawa Y., Tsuboi N., Maruyama S., Morita Y., Matsuguchi T., Matsuo S. Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: the role of Toll-like receptor 4. J. Am. Soc. Nephrol. 2004, 15:1289-1299.
38. Park J.H., Kim Y.G., Shaw M., Kanneganti T.D., Fujimoto Y., Fukase K., Inohara N., Núñez G. Nod1/RICK and TLR signaling regulate chemokine and antimicrobial innate immune responses in mesothelial cells. J. Immunol. 2007, 179:514-521.
39. Hussain T., Nasreen N., Lai Y., Bellew B.F., Antony V.B., Mohammed K.A. Innate immune responses in murine pleural mesothelial cells: Toll-like receptor-2 dependent induction of beta-defensin-2 by staphylococcal peptidoglycan. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L461-470.
40. Wu J., Yang X., Zhang Y.F., Zhou S.F., Zhang R., Dong X.Q., Fan J.J., Liu M., Yu X.Q. Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflamm. Res. 2009, 58:473-482.
41. Wörnle M., Sauter M., Kastenmüller K., Ribeiro A., Roeder M., Mussack T., Ladurner R., Sitter T. Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma. Cell. Biol. Int. 2009, 33:180-186.
42. Wörnle M., Sauter M., Kastenmüller K., Ribeiro A., Roeder M., Schmid H., Krötz F., Mussack T., Ladurner R., Sitter T. Novel role of Toll-like receptor 3, RIG-I and MDA5 in poly (I:C) RNA-induced mesothelial inflammation. Mol. Cell. Biochem. 2009, 322:193-206.
43. Wörnle M., Sauter M., Kastenmüller K., Ribeiro A., Mussack T., Ladurner R., Sitter T. Role of viral receptors TLR3, RIG-I and MDA5 in mesothelial tissue-type plasminogen activator and plasminogen activator inhibitor-1 synthesis. Thromb. Haemost. 2009, 101:1128-1137.
44. Merkle M., Ribeiro A., Sauter M., Ladurner R., Mussack T., Sitter T., Wörnle M. Effect of activation of viral receptors on the gelatinases MMP-2 and MMP-9 in human mesothelial cells. Matrix Biol. 2010, 29:202-208.
45. Colmont C.S., Raby A.C., Dioszeghy V., Lebouder E., Foster T.L., Jones S.A., Labéta M.O., Fielding C.A., Topley N. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrol. Dial. Transplant. 2011, 26:4079-4090.
46. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2010, 101:1-6.
47. Frizelle S.P., Grim J., Zhou J., Gupta P., Curiel D.T., Geradts J., Kratzke R.A. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998, 16:3087-3095.
48. Frizelle S.P., Rubins J.B., Zhou J.X., Curiel D.T., Kratzke R.A. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther. 2000, 7:1421-1425.
49. Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., Testa J.R. P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994, 54:5547-5551.
50. Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K., Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M., Sekido Y. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007, 98:438-446.
51. Altomare D.A., Menges C.W., Pei J., Zhang L., Skele-Stump K.L., Carbone M., Kane A.B., Testa J.R. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc. Natl. Acad. Sci. USA 2009, 106:3420-3425.
52. Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995, 55:1227-1231.
53. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., Klein W.M., Jhanwar S.C., Seizinger B., Kley N., Klein-Szanto A.J., Testa J.R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. USA 1995, 92:10854-10858.
54. McClatchey A.I., Giovannini M. Membrane organization, tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev. 2005, 19:2265-2277.
55. Jin H., Sperka T., Herrlich P., Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 2006, 442:576-579.
56. Yokoyama T., Osada H., Murakami H., Tatematsu Y., Taniguchi T., Kondo Y., Yatabe Y., Hasegawa Y., Shimokata K., Horio Y., Hida T., Sekido Y. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008, 29:2139-2146.
57. Lopez-Lago M.A., Okada T., Murillo M.M., Socci N., Giancotti F.G. Loss of the tumor suppressor NF2, encoding Merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 2009, 29:4235-4249.
58. Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R.A., Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung. Cancer 2009, 64:140-147.
59. Guled M., Lahti L., Lindholml P.M., Salmenkivi K., Bagwan I., Nicholson A.G., Knuutila S. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009, 48:615-623.
60. Janssen Y.M., Heintz N.H., Mossman B.T. Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-Lcysteine in mesothelial cells. Cancer Res. 1995, 55:2085-2089.
61. Yuan Z., Taatjes D.J., Mossman B.T., Heintz N.H. The duration of nuclear extracellular signal-regulated kinase 1 and 2 signaling during cell cycle reentry distinguishes proliferation from apoptosis in response to asbestos. Cancer Res. 2004, 64:6530-6536.
62. Ramos-Nino M.E., Scapoli L., Martinelli M., Land S., Mossman B.T. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res. 2003, 63:3539-3545.
63. Ivanov S.V., Miller J., Lucito R., Tang C., Ivanova A.V., Pei J., Carbone M., Cruz C., Beck A., Webb C., Nonaka D., Testa J.R., Pass H.I. Genomic events associated with progression of pleural malignant mesothelioma. Int. J. Cancer 2009, 124:589-599.
64. Peralta Soler A., Knudsen K.A., Jaurand M.C., Johnson K.R., Wheelock M.J., Klein-Szanto A.J., Salazar H. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum. Pathol. 1995, 26:1363-1369.
65. Govindan R., Kratzke R.A., Herndon J.E., Niehans G.A., Vollmer R., Watson D., Green M.R., Kindler H.L. Cancer and Leukemia Group B (CALGB 30101), Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 2005, 11:2300-2304.
66. Zanella C.L., Posada J., Tritton T.R., Mossman B.T. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated Red in Translation 137 protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 1996, 56:5334-5338.
67. Manning C.B., Cummins A.B., Jung M.W., Berlanger I., Timblin C.R., Palmer C., Taatjes D.J., Hemenway D., Vacek P., Mossman B.T. A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res. 2002, 62:4169-4175.
68. Pache J.C., Janssen Y.M., Walsh E.S., Quinlan T.R., Zanella C.L., Low R.B., Taatjes D.J., Mossman B.T. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am. J. Pathol. 1998, 152:333-340.
69. Suzuki Y., Murakami H., Kawaguchi K., Tanigushi T., Fujii M., Shinjo K., Kondo Y., Osada H., Shimokata K., Horio Y., Hasegawa Y., Hida T., Sekido Y. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol. Med. Report 2009, 2:181-188.
70. Destro A., Ceresoli G.L., Baryshnikova E., Garassino I., Zucali P.A., De Vincenzo F., Bianchi P., Morenghi E., Testori A., Alloisio M., Santoro A., Roncalli M. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Lung. Cancer 2008, 59:369-376.
71. Ji L., Minna J.D., Roth J.A. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005, 1:79-92.
72. Izzi V., Chiurchiù V., D'Aquilio F., Palumbo C., Tresoldi I., Modesti A., Baldini P.M. Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. Int. J. Oncol. 2009, 34:543-550.
73. Martinet N., Beck G., Bernard V., Plenat F., Vaillant P., Schooneman F., Vignaud J.M., Martinet Y. Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity. Cancer 1992, 70:854-860.
74. Alexandrakis M.G., Coulocheri S.A., Bouros D., Mandalaki K., Karkavitsas N., Eliopoulos G.D. Evaluation of inflammatory cytokines in malignant and benign pleural effusions. Oncol. Rep. 2000, 7:1327-1332.
75. Nabil K., Rihn B., Jaurand M.C., Vignaud J.M., Ripoche J., Martinet Y., Martinet N. Identification of human complement factor H as a chemotactic protein for monocytes. Biochem. J. 1997, 326:377-383.
76. Miselis N.R., Lau B.W., Wu Z., Kane A.B. Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma. Cancer Microenviron. 2011, 4:39-50.
77. Kennedy B.C., Shimato S., Anderson R.C., Bruce J.N. Defining the mechanisms of CD8 T-cell tumor tolerance. Immunotherapy 2011, 3:23-26.
78. Pan P.Y., Ma G., Weber K.J., Ozao-Choy J., Wang G., Yin B., Divino C.M., Chen S.H. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010, 70:99-108.
79. Greten T.F., Manns M.P., Korangy F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 2011, 11:802-806.
80. Greifenberg V., Ribechini E., Rossner S., Lutz M.B. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 2009, 39:2865-2876.
81. Veltman J.D., Lambers M.E., van Nimwegen M., Hendriks R.W., Hoogsteden H.C., Aerts J.G., Hegmans J.P. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma, Celecoxib influences MDSC function. BMC Cancer 2010, 30:464-476.
82. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., Zanon A., Rossi C.R., Nitti D., Bronte V., Zanovello P. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 2009, 182:6562-6568.
83. Cuenca A.G., Delano M.J., Kelly-Scumpia K.M., Moreno C., Scumpia P.O., Laface D.M., Heyworth P.G., Efron P.A., Moldawer L.L. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 2011, 17:281-292.
84. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 2007, 13:5243-5248.
85. Burt B.M., Rodig S.J., Tilleman T.R., Elbardissi A.W., Bueno R., Sugarbaker D.J. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011.
86. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. TRENDS Immunol. 2002, 23:549-555.
87. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196:254-265.
88. Sica A., Saccani A., Mantovani A. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2002, 2:1045-1054.
89. Bielefeldt-Ohmann H., Fitzpatrick D.R., Marzo A.L., Jarnicki A.G., Himbeck R.P., Davis M.R., Manning L.S., Robinson B.W. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol. Immunother. 1994, 39:347-359.
90. Hegmans J.P., Hemmes A., Hammad H., Boon L., Hoogsteden H.C., Lambrecht B.N. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 2006, 27:1086-1095.
91. Miselis N.R., Wu Z.J., Van Rooijen N., Kane A.B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 2008, 7:788-799.
92. Veltman J.D., Lambers M.E., van Nimwegen M., Hendriks R.W., Hoogsteden H.C., Hegmans J.P., Aerts J.G. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br. J. Cancer 2010, 103:629-641.
93. Manning L.S., Bowman R.V., Darby S.B., Robinson B.W. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am. Rev. Respir. Dis. 1989, 139:1369-1374.
94. Mavaddat N., Robinson B.W., Rose A.H., Manning L.S., Garlepp M.J. An analysis of the relationship between γδ T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity. Immunol. Cell. Biol. 1993, 71:27-37.
95. Mutti L., Valle M.T., Balbi B., Orengo A.M., Lazzaro A., Alciato P., Gatti E., Betta P.G., Pozzi E. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int. J. Cancer 1998, 78:740-749.
96. Jackaman C., Cornwall S., Lew A.M., Zhan Y., Robinson B.W., Nelson D.J. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur. Respir. J. 2009, 34:162-175.
97. DeLong P., Carroll R.G., Henry A.C., Tanaka T., Ahmad S., Leibowitz M.S., Sterman D.H., June C.H., Albelda S.M., Vonderheide R.H. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol. Ther. 2005, 4:342-346.
98. Rudge G., Barrett S.P., Scott B., van Driel I.R. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. J. Immunol. 2007, 178:4089-4096.
99. Anraku M., Cunningham K.S., Yun Z., Tsao M.S., Zhang L., Keshavjee S., Johnston M.R., de Perrot M. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2008, 135:823-829.
100. van der Most R.G., Currie A.J., Mahendran S., Prosser A., Darabi A., Robinson B.W., Nowak A.K., Lake R.A. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 2009, 58:1219-1228.
101. Shimizu Y., Dobashi K., Imai H., Sunaga N., Ono A., Sano T., Hikino T., Shimizu K., Tanaka S., Ishizuka T., Utsugi M., Mori M. CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma. Int. J. Immunopathol. Pharmacol. 2009, 22:43-51.
102. Wu L., Yun Z., Tagawa T., Rey-McIntyre K., Anraku M., de Perrot M. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model. J. Thorac. Oncol. 2011.
103. Ho M., Hassan R., Zhang J., Wang Q.C., Onda M., Bera T., Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res. 2005, 11:3814-3820.
104. Shigematsu Y., Hanagiri T., Kuroda K., Baba T., Mizukami M., Ichiki Y., Yasuda M., Takenoyama M., Sugio K., Yasumoto K. Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers. Cancer Sci. 2009, 100:1326-1334.
105. Robinson C., Callow M., Stevenson S., Scott B., Robinson B.W., Lake R.A. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am. J. Respir. Cell. Mol. Biol. 2000, 22:550-556.
106. Otsuki T., Maeda M., Murakami S., Hayashi H., Miura Y., Kusaka M., Nakano T., Fukuoka K., Kishimoto T., Hyodoh F., Ueki A., Nishimura Y. Immunological effects of silica and asbestos. Cell. Mol. Immunol. 2007, 4:261-268.
107. Selleslag D.L., Geraghty R.J., Ganesan T.S., Slevin M.L., Wrigley P.F., Brown R. Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma. Acta Clin. Belg. 1989, 44:199-201.
108. Ozkan M., Eser B., Er O., Altuntas F., Coskun R., Topsakal R., Mavili E., Kala M., Altinbas M. Antiphospholipid syndrome associated with malignant mesothelioma presenting with superior vena cava thrombosis: a case report. Clin. Appl. Thromb. Hemost. 2004, 10:393-396.
109. Wu P., Hyodoh F., Hatayama T., Sakaguchi H., Hatada S., Miura Y., Takata-Tomokuni A., Katsuyama H., Otsuki T. Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A. Immunol. Lett. 2005, 98:145-152.
110. Bard M.P., Hegmans J.P., Hemmes A., Luider T.M., Willemsen R., Severijnen L.A., van Meerbeeck J.P., Burgers S.A., Hoogsteden H.C., Lambrecht B.N. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell. Mol. Biol. 2004, 31:114-121.
111. Hegmans J.P., Bard M.P., Hemmes A., Luider T.M., Kleijmeer M.J., Prins J.B., Zitvogel L., Burgers S.A., Hoogsteden H.C., Lambrecht B.N. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am. J. Pathol. 2004, 164:1807-1815.
112. Clayton A., Mitchell J.P., Court J., Mason M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Res. 2007, 67:7458-7466.
113. Clayton A., Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol. Dis. 2005, 34:206-213.
114. Clayton A., Al-Taei S., Webber J., Mason M.D., Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 2011, 187:676-683.
115. Tabata Y., Ikada Y. Drug delivery systems for antitumor activation of macrophages. Crit. Rev. Ther. Drug Carrier Syst. 1990, 7:121-148.
116. Pimm M.V., Baldwin R.W. BCG therapy of pleural and peritoneal growth of transplanted rat tumours. Int. J. Cancer 1975, 15:260-269.
117. Webster I., Cochrane J.W., Burkhardt K.R. Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S. Afr. Med. J. 1982, 61:277-278.
118. O'Brien M.E., Saini A., Smith I.E., Webb A., Gregory K., Mendes R., Ryan C., Priest K., Bromelow K.V., Palmer R.D., Tuckwell N., Kennard D.A., Souberbielle B.E. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br. J. Cancer 2000, 83:853-857.
119. Pandha H.S., Mortimer P., Souberbeille B., McCoubrie P., O'Brien M.E. Cutaneous toxicity after intradermal vaccination with Mycobacterium vaccae against lung cancer and malignant mesothelioma. Br. J. Dermatol. 2001, 144:648-649.
120. Mendes R., O'Brien M.E., Mitra A., Norton A., Gregory R.K., Padhani A.R., Bromelow K.V., Winkley A.R., Ashley S., Smith I.E., Souberbielle B.E. Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br. J. Cancer 2002, 86:336-341.
121. Rosso R., Rimoldi R., Salvati F., De Palma M., Cinquegrana A., Nicoló G., Ardizzoni A., Fusco U., Capaccio A., Centofanti R., Neri M., Cruciani A.R., Maisto L. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988, 45:253-256.
122. Hand A., Pelin K., Mattson K., Linnainmaa K. Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 1995, 6:77-82.
123. Gattacceca F., Pilatte Y., Billard C., Monnet I., Moritz S., Le Carrou J., Eloit M., Jaurand M.C. Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin. Cancer Res. 2002, 8:3298-3304.
124. Monnet I., Breau J.L., Moro D., Lena H., Eymard J.C., Ménard O., Vuillez J.P., Chokri M., Romet-Lemonne J.L., Lopez M. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002, 121:1921-1927.
125. Sterman D.H., Recio A., Haas A.R., Vachani A., Katz S.I., Gillespie C.T., Cheng G., Sun J., Moon E., Pereira L., Wang X., Heitjan D.F., Litzky L., June C.H., Vonderheide R.H., Carroll R.G., Albelda S.M. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol. Ther. 2010, 18:852-860.
126. Willmon C.L., Saloura V., Fridlender Z.G., Wongthida P., Diaz R.M., Thompson J., Kottke T., Federspiel M., Barber G., Albelda S.M., Vile R.G. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009, 69:7713-7720.
127. Li H., Peng K.W., Dingli D., Kratzke R.A., Russell S.J. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene. Ther. 2010, 17:550-558.
128. Lissoni P., Barni S., Ardizzoia A., Paolorossi F., Tisi E., Crispino S., Tancini G. Intracavitary administration of Interleukin-2 as palliative therapy for neoplastic effusions. Tumori 1992, 30:118-120.
129. Nano R., Capelli E., Civallero M., Terzuolo G., Volpini E., Nascimbene C., Cremaschi P. Effects of Interleukin-2 for the treatment of malignant mesothelioma. Oncol. Rep. 1998, 5:489-492.
130. Goey S.H., Eggermont A.M., Punt C.J., Slingerland R., Gratama J.W., Oosterom R., Oskam R., Bolhuis R.L., Stoter G. Intrapleural administration of Interleukin 2 in pleural mesothelioma: a phase I-II study. Br. J. Cancer 1995, 72:1283-1288.
131. Jackaman C., Bundell C.S., Kinnear B.F., Smith A.M., Filion P., van Hagen D., Robinson B.W., Nelson D.J. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. 2003, 171:5051-5063.
132. Alì G., Boldrini L., Lucchi M., Picchi A., Dell'Omodarme M., Prati M.C., Mussi A., Corsi V., Fontanini G. Treatment with Interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br. J. Cancer 2009, 101:1869-1875.
133. Dirix L.Y., van Meerbeeck J., Schrijvers D., Corthouts B., Prové A., van Marck E., Vermeire P., van Oosterom A.T. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann. Oncol. 1994, 5:653-655.
134. Davidson J.A., Musk A.W., Wood B.R., Morey S., Ilton M., Yu L.L., Drury P., Shilkin K., Robinson B.W. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J. Immunother. 1998, 21:389-398.
135. Triozzi P.L., Aldrich W., Allen K.O., Lima J., Shaw D.R., Strong T.V. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int. J. Cancer 2005, 113:406-414.
136. Yoshimoto A., Kasahara K., Saito K., Fujimura M., Nakao S. Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma with the expression of other cytokines. Int. J. Clin. Oncol. 2005, 10:58-62.
137. Powell A., Creaney J., Broomfield S., Van Bruggen I., Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung. Cancer 2006, 52:189-197.
138. Leong C., Marley J., Loh S., Robinson B., Garlepp M. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. Cancer Gene. Ther. 1996, 3:321-330.
139. Leong C.C., Marley J.V., Loh S., Milech N., Robinson B.W., Garlepp M.J. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int. J. Cancer 1997, 71:476-482.
140. van der Most R.G., Himbeck H., Aarons S., Carter S.J., Larma I., Robinson C., Currie A., Lake R.A. Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. J. Immunother. 2006, 29:134-142.
141. Stone G.W., Barzee S., Snarsky V., Santucci C., Tran B., Kornbluth R.S. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA. J. Thorac. Oncol. 2009, 4:802-808.
142. Broomfield S.S., van der Most R.G., Prosser A.C., Mahendran S., Tovey M.G., Smyth M.J., Robinson B.W., Currie A.J. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 2009, 182:5217-5224.
143. Bradish C.J., Allner K., Fitzgeorge R. Immunomodification and the expression of virulence in mice by defined strains of semliki forest virus: the effects of cyclophosphamide. J. Gen. Virol. 1975, 28:225-237.
144. Mamede M., Saga T., Ishimori T., Nakamoto Y., Sato N., Higashi T., Mukai T., Kobayashi H., Konishi J. Differential uptake of (18)F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification. Neoplasia 2003, 5:179-183.
145. Yanagawa H., Sone S., Fukuta K., Nishioka Y., Ogura T. Local adoptive immunotherapy using lymphokine-activated killer cells and Interleukin-2 against malignant pleural mesothelioma: report of two cases. Jpn. J. Clin. Oncol. 1991, 21:377-383.
146. Tani M., Tanimura H., Yamaue H., Mizobata S., Yamamoto M., Iwahashi M., Ura K., Nagai Y., Tsunoda T., Wakasaki H., Nanjo K., Fujino K., Yukawa S. Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases. Surg. Today 1998, 28:647-651.
147. Hegmans J.P., Hemmes A., Aerts J.G., Hoogsteden H.C., Lambrecht B.N. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 2005, 171:1168-1177.
148. Jackaman C., Cornwall S., Graham P.T., Nelson D.J. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol. Cell. Biol. 2011, 89:255-267.
149. Zhao Y., Moon E., Carpenito C., Paulos C.M., Liu X., Brennan A.L., Chew A., Carroll R.G., Scholler J., Levine B.L., Albelda S.M., June C.H. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010, 70:9053-9061.
150. Plautz G.E., Cohen P.A., Shu S. Considerations on clinical use of T cell immunotherapy for cancer. Arch. Immunol. Ther. Exp. 2003, 51:245-257.
151. Jassar A.S., Suzuki E., Kapoor V., Sun J., Silverberg M.B., Cheung L., Burdick M.D., Strieter R.M., Ching L.M., Kaiser L.R., Albelda S.M. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005, 65:11752-11761.
152. Chang K., Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int. J. Cancer 1994, 57:90-97.
153. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 1996, 93:136-140.
154. Argani P., Iacobuzio-Donahue C., Ryu B., Rosty C., Goggins M., Wilentz R.E., Murugesan S.R., Leach S.D., Jaffee E., Yeo C.J., Cameron J.L., Kern S.E., Hruban R.H. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 2001, 7:3862-3868.
155. Yokokawa J., Palena C., Arlen P., Hassan R., Ho M., Pastan I., Schlom J., Tsang K.Y. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin. Cancer Res. 2005, 11:6342-6351.
156. Jasani B., Jones C.J., Radu C., Wynford-Thomas D., Navabi H., Mason M., Adams M., Gibbs A. Simian virus 40 detection in human mesothelioma: reliability and significance of the available molecular evidence. Front. Biosci. 2001, 6:E12-E22.
157. Elmishad A.G., Bocchetta M., Pass H.I., Carbone M. Polio vaccines, SV40 and human tumours, an update on false positive and false negative results. Dev. Biol. 2006, 123:109-117.
158. Xie Y.C., Hwang C., Overwijk W., Zeng Z., Eng M.H., Mulé J.J., Imperiale M.J., Restifo N.P., Sanda M.G. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J. Natl. Cancer Inst. 1999, 91:169-175.
159. Bright R.K., Kimchi E.T., Shearer M.H., Kennedy R.C., Pass H.I. SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients. Cancer Immunol. Immunother. 2002, 50:682-690.
160. Park S., Schalling M., Bernard A., Maheswaran S., Shipley G.C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G., Griffin J., Minden M., Housman D.E., Haber D.A. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat. Genet. 1993, 4:415-420.
161. Ordóñez N.G. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch. Pathol. Lab. Med. 2005, 129:1407-1414.
162. Bei R., Scardino A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J. Biomed. Biotechnol. 2010, 2010:102758.
163. May R.J., Dao T., Pinilla-Ibarz J., Korontsvit T., Zakhaleva V., Zhang R.H., Maslak P., Scheinberg D.A. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin. Cancer Res. 2007, 13:4547-4555.
164. Krug L.M., Dao T., Brown A.B., Maslak P., Travis W., Bekele S., Korontsvit T., Zakhaleva V., Wolchok J., Yuan J., Li H., Tyson L., Scheinberg D.A. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol. Immunother. 2010, 59:1467-1479.
165. Palumbo C., Bei R., Procopio A., Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. Curr. Med. Chem. 2008, 15:855-867.
166. Nowak A.K., Lake R.A., Kindler H.L., Robinson B.W. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin. Oncol. 2002, 29:82-96.
167. Chang C.L., Wu T.C., Hung C.F. Control of human mesothelin-expressing tumors by DNA vaccines. Gene. Ther. 2007, 14:1189-1198.
168. Mukherjee S., Nelson D., Loh S., van Bruggen I., Palmer L.J., Leong C., Garlepp M.J., Robinson B.W. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene. Ther. 2001, 8:580-588.
169. Grégoire M., Ligeza-Poisson C., Juge-Morineau N., Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 2003, 21:791-794.
170. Ebstein F., Sapede C., Royer P.J., Marcq M., Ligeza-Poisson C., Barbieux I., Cellerin L., Dabouis G., Grégoire M. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 2004, 169:1322-1330.
171. King J.E., Thatcher N., Pickering C.A., Hasleton P.S. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006, 48:223-232.
172. Hsu S.M., Hsu P.L., Zhao X., Kao-Shan C.S., Whang-Peng J. Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential. Cancer Res. 1988, 48:5228-5236.
173. Griffin T.W., Collins J., Bokhari F., Stochl M., Brill A.B., Ito T., Emond G., Sands H. Intraperitoneal immunoconjugates. Cancer Res. 1990, 50:1031-1038.
174. Griffin T.W., Stocl M., Collins J., Fernandes J., Maher V.E. Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. J. Immunother. 1992, 11:12-18.
175. Chang K., Pai L.H., Pass H., Pogrebniak H.W., Tsao M.S., Pastan I., Willingham M.C. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am. J. Surg. Pathol. 1992, 16:259-268.
176. Brinkmann U., Webber K., Di Carlo A., Beers R., Chowdhury P., Chang K., Chaudhary V., Gallo M., Pastan I. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int. J. Cancer 1997, 71:638-644.
177. Chowdhury P.S., Viner J.L., Beers R., Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 1998, 95:669-674.
178. Chowdhury P.S., Vasmatzis G., Beers R., Lee B., Pastan I. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol. 1998, 281:917-928.
179. Hassan R., Ebel W., Routhier E.L., Patel R., Kline J.B., Zhang J., Chao Q., Jacob S., Turchin H., Gibbs L., Phillips M.D., Mudali S., Iacobuzio-Donahue C., Jaffee E.M., Moreno M., Pastan I., Sass P.M., Nicolaides N.C., Grasso L. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007, 7:20-30.
180. Hassan R., Cohen S.J., Phillips M., Pastan I., Sharon E., Kelly R.J., Schweizer C., Weil S., Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin. Cancer Res. 2010, 16:6132-6138.
181. Feng Y., Xiao X., Zhu Z., Streaker E., Ho M., Pastan I., Dimitrov D.S. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol. Cancer Ther. 2009, 8:1113-1118.
182. Ho M., Feng M., Fisher R.J., Rader C., Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int. J. Cancer 2011, 128:2020-2030.
183. Inami K., Abe M., Takeda K., Hagiwara Y., Maeda M., Segawa T., Suyama M., Watanabe S., Hino O. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci. 2010, 101:969-974.
184. Chowdhury P.S., Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 1999, 17:568-572.
185. Sato N., Hassan R., Axworthy D.B., Wong K.J., Yu S., Theodore L.J., Lin Y., Park L., Brechbiel M.W., Pastan I., Paik C.H., Carrasquillo J.A. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J. Nucl. Med. 2005, 46:1201-1209.
186. Bera T.K., Williams-Gould J., Beers R., Chowdhury P., Pastan I. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer. Mol. Cancer Ther. 2001, 1:79-84.
187. Wang B., Kuroiwa J.M., He L.Z., Charalambous A., Keler T., Steinman R.M. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann. N.Y. Acad. Sci. 2009, 1174:6-17.
188. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
189. He B., You L., Uematsu K., Xu Z., Lee A.Y., Matsangou M., McCormick F., Jablons D.M. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004, 6:7-14.
190. Mazieres J., You L., He B., Xu Z., Twogood S., Lee A.Y., Reguart N., Batra S., Mikami I., Jablons D.M. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int. J. Cancer 2005, 117:326-332.
191. Inamoto T., Yamada T., Ohnuma K., Kina S., Takahashi N., Yamochi T., Inamoto S., Katsuoka Y., Hosono O., Tanaka H., Dang N.H., Morimoto C. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin. Cancer Res. 2007, 13:4191-4200.
192. V. Gregorc, G.L. Ceresoli, P.A. Zucali, F.G. De Braud, E. Bajetta, A. Santoro, M.G. Viganò, F. Caligaris Cappio, A. Lambiase, C. Bordignon, Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in: Previously Treated Patients with Malignant Pleural Mesothelioma (MPM), ASCO Abstract # 7582.
193. V. Gregorc, G.L. Ceresoli, P.A. Zucali, V. Gregorc, G.L. Ceresoli, P.A. Zucali, F.G. De Braud, E. Bajetta, A. Santoro, M.G. Viganò, F. Caligaris Cappio, A. Lambiase, C. Bordignon, NGR-hTNF, a vascular targeting agent (VTA), in: Previously Treated Patients with Malignant Pleural Mesothelioma (MPM): A Phase II Study, ECCO 15-34th ESMO 2009 - Abstract # 9011.